Search Result

Pathways Recommended:	Protein Tyrosine Kinase/RTK

Results for "

Calmodulin-dependent kinases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CaMK (33) AMPK (3) Amyloid-β (1) Antibiotic (1) Apoptosis (7) Autophagy (10) Bacterial (2) Calcineurin (1) Calmodulin (7) Caspase (1) Checkpoint Kinase (Chk) (1) Cholinesterase (ChE) (2) DNA/RNA Synthesis (2) EGFR (1) MAPKAPK2 (MK2) (1) MEK (1) Mixed Lineage Kinase (1) Myosin (4) Na+/K+ ATPase (1) NF-κB (1) NO Synthase (2) Nucleoside Antimetabolite/Analog (2) P2X Receptor (1) Phosphatase (2) Phosphodiesterase (PDE) (5) PKA (1) PKC (8) Potassium Channel (3) PROTACs (1) Proteasome (1) Reference Standards (2) RIP kinase (1) Ser/Thr Kinase (2) Src (1) Tau Protein (1) Trk Receptor (1)
By Research Areas:	Cancer (11) Cardiovascular Disease (5) Infection (3) Inflammation/Immunology (1) Metabolic Disease (8) Neurological Disease (24)

By Targets:

CaMK (33)

AMPK (3)

Amyloid-β (1)

Antibiotic (1)

Apoptosis (7)

Autophagy (10)

Bacterial (2)

Calcineurin (1)

Calmodulin (7)

Caspase (1)

Checkpoint Kinase (Chk) (1)

Cholinesterase (ChE) (2)

DNA/RNA Synthesis (2)

EGFR (1)

MAPKAPK2 (MK2) (1)

MEK (1)

Mixed Lineage Kinase (1)

Myosin (4)

Na+/K+ ATPase (1)

NF-κB (1)

NO Synthase (2)

Nucleoside Antimetabolite/Analog (2)

P2X Receptor (1)

Phosphatase (2)

Phosphodiesterase (PDE) (5)

PKA (1)

PKC (8)

Potassium Channel (3)

PROTACs (1)

Proteasome (1)

Reference Standards (2)

RIP kinase (1)

Ser/Thr Kinase (2)

Src (1)

Tau Protein (1)

Trk Receptor (1)

By Research Areas:

Cancer (11)

Cardiovascular Disease (5)

Infection (3)

Inflammation/Immunology (1)

Metabolic Disease (8)

Neurological Disease (24)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: CaMK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15465

KN-93 Maximum Cited Publications 95 Publications Verification	CaMK Autophagy	Cancer
KN-93 is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (CaMKII) with a K_i of 370 nM.

HY-19805

STO-609 30+ Cited Publications	CaMK AMPK Autophagy	Metabolic Disease
STO-609 is a selective and cell-permeable inhibitor of the Ca ²⁺/calmodulin-dependent protein kinase kinase (CaM-KK), with K_i values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC₅₀ ~0.02 g/ml.

HY-N6732

K-252a 25+ Cited Publications SF2370; Antibiotic K 252a; Antibiotic SF 2370	Autophagy PKA PKC Trk Receptor CaMK	Infection Inflammation/Immunology
K-252a, a staurosporine analog, inhibits protein kinase, with IC₅₀ values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca ²⁺/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively . K-252a is a potent inhibitor (IC₅₀ of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene .

HY-13290

KN-62 10+ Cited Publications	CaMK P2X Receptor	Metabolic Disease Cancer
KN-62 is a selective and reversible inhibitor of calmodulin-dependent protein kinase II (CaMK-II) with a K_i of 0.9 μM for rat brain CaMK-II. KN-62 directly binds to the calmodulin binding site of CaMK-II. KN-62 displays noncompetitive antagonism at P2X₇ receptors in HEK293 cells, with an IC₅₀ value of approximately 15 nM.

HY-Z0478

(-)-Limonene 1 Publications Verification (S)-(-)-Limonene	Bacterial Antibiotic CaMK	Infection Cardiovascular Disease Metabolic Disease
(-)-Limonene ((S)-(-)-Limonene) is orally active and can cause mild bronchoconstriction. (-)-Limonene alleviates cytosolic and mitochondrial oxidative stress by inhibiting the increase of calcium ions (Ca ²⁺) and Ca ²⁺/calmodulin-dependent protein kinase II (CaMKII). It also exerts anti-stress effects by inhibiting the activity of the hypothalamic-pituitary-adrenal (HPA) axis. Additionally, (-)-Limonene can be used as an antibacterial agent in aquaculture .

HY-108599

DCP-LA 5+ Cited Publications FR236924	PKC CaMK Phosphatase Apoptosis	Neurological Disease
DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. DCP-LA activates Ca( ²⁺)/calmodulin-dependent protein kinase II (CaMKII) and inhibits protein phosphatase-1 (PP-1) to stimulate AMPA receptor exocytosis. DCP-LA inhibits activation of caspase-3/-9 and protects neurons at least in part from oxidative stress-induced apoptosis .

HY-100912

W-7 hydrochloride 5+ Cited Publications	Phosphodiesterase (PDE) Myosin Apoptosis Calmodulin Potassium Channel	Cancer
W-7 hydrochloride is a selective *calmodulin* antagonist. W-7 hydrochloride inhibits the Ca ²⁺-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC₅₀ values of 28 μM and 51 μM, respectively. W-7 hydrochloride induces apoptosis and has antitumor and vascular relaxing activity. W-7 hydrochloride is a blocker of Kv4.3 and can be used for research of arrhythmias .

HY-15465B

KN-93 phosphate Maximum Cited Publications 95 Publications Verification	CaMK Autophagy	Cancer
KN-93 phosphate is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (CaMKII) with a Ki of 370 nM .

HY-P1821

Myelin Basic Protein 2 Publications Verification MHP4-14	PKC	Neurological Disease
Myelin Basic Protein (MHP4-14), a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (K_m=7 μM). Myelin Basic Protein is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca ²⁺/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts .

HY-148907

CS640	CaMK MEK Mixed Lineage Kinase RIP kinase Tau Protein	Neurological Disease
CS640 (Compound 19) is a chemical probe and a calmodulin-dependent kinase inhibitor. CS640 inhibits CaMK1D, CaMK1B, CaMK1A, CaMK1G, MEK5, RIPK4, mLK3 and PIP5K1, with IC₅₀ values of 8, 3, 1, 1, 25 nM, 5.69, 2.75 and 11.2 μM, respectively. CS640 blocks Aβ-induced hyperphosphorylation of tau protein at the Thr181 site, but fails to protect primary mouse cortical neurons from Aβ-induced toxic damage. CS640 is applicable to research related to Alzheimer's disease .

HY-15465A

KN-93 hydrochloride Maximum Cited Publications 95 Publications Verification	CaMK Autophagy	Cancer
KN-93 hydrochloride is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (CaMKII) with a K_i of 370 nM.

HY-115719

NR162	Ser/Thr Kinase	Neurological Disease
NR162 is a selective CASK (Ca ²⁺/calmodulin-dependent Ser/Thr kinase) inhibitor with an IC₅₀ of 80 nM and a Kd of 22 nM. NR162 shows about 50-fold selectivity for CASK than TYRO3. NR162 targets the unique GFG motif of CASK and has excellent shape complementarity to the CASK ATP binding pocket. NR162 can be used for the research of neurological diseases .

HY-110140

(E)-KN-93 phosphate	CaMK	Cardiovascular Disease Neurological Disease
(E)-KN-93 phosphate is a *Ca ²⁺/calmodulin-dependent* protein kinase II (CaMKII) inhibitor with IC₅₀ values of 9 μM and 3 μM against CaMKIIδ_Monomer and CaMKIIδ_Dodecamer**, respectively. (E)-KN-93 phosphate can be used in research on epilepsy, depression, and arrhythmias. .

HY-100779

Rimacalib SMP 114	CaMK Autophagy	Metabolic Disease
Rimacalib (SMP 114) is a *Ca ²⁺/calmodulin-dependent* protein kinase II (CaMKII) inhibitor, with IC₅₀s of ~1 μM for CaMKIIα to ~30 μM for CaMKIIγ** .

HY-P0225

Autocamtide 2 Autocamtide II	CaMK Autophagy	Neurological Disease
Autocamtide 2 is a highly selective peptide substrate of calcium/calmodulin-dependent protein kinase II (CaMKII). It can be used in the CaMKII activity assay.

HY-W013857

Lavendustin C	CaMK EGFR Src	Cancer
Lavendustin C is a potent *Ca ²⁺ calmodulin-dependent* kinase II (CaMK II) inhibitor with an IC₅₀ of 0.2 µM. Lavendustin C inhibits EGFR*-associated tyrosine kinase* (IC₅₀=0.012 µM) and pp60 ^c-src(+) kinase (IC₅₀=0.5 µM) .

HY-168905

SGC-CAMKK2-1	Calmodulin	Cancer
SGC-CAMKK2-1, a chemical probe, is the selective, inhibitor for calcium/calmodulin-dependent protein kinase kinase 2 (CAMKK2) with an IC₅₀ of 30 nM. SGC-CAMKK2-1 inhibits AMPK phosphorylation in cell C4-2 with an IC₅₀ of 1.6 μM .

HY-N1989

Bacoside A	Na+/K+ ATPase CaMK Apoptosis Cholinesterase (ChE) NO Synthase NF-κB	Neurological Disease Cancer
Bacoside A is an orally active, blood-brain barrier-permeable triterpenoid saponin that modulates the activities of ATPases, AChE, CaMK2A and iNOS. Derived from Bacopa monniera. Bacoside A exerts significant antioxidant, anti-inflammatory and anti-apoptotic effects by maintaining ion balance, scavenging reactive oxygen species, stabilizing cell membranes, and regulating the expression of NF-κB and apoptosis-related proteins. Bacoside A counteracts morphine-induced reductions in Na ⁺/K ⁺-ATPase, Ca ²⁺-ATPase and Mg ²⁺-ATPase activities, increases mitochondrial membrane potential, and decreases intracellular reactive oxygen species levels. Bacoside A specifically binds to calcium/calmodulin-dependent protein kinase IIA to trigger endoplasmic reticulum calcium release. Bacoside A exhibits non-apoptotic cytotoxicity against glioblastoma cells while protecting normal nerve cells from stress-induced damage. Bacoside A is applicable to the research of Parkinson's disease and glioblastoma multiforme .

HY-P3811A

Autocamtide-3 acetate	CaMK	Neurological Disease
Autocamtide-3 acetate, a 13-amino-acid peptide containing Thr287, is a selective *CaMKII (Ca ²⁺/calmodulin-dependent* kinase II)** (CaMK) substrate .

HY-146268

CaMKIIα-IN-1	CaMK	Neurological Disease
CaMKIIα-IN-1 (Compound 4d) is an orally active *Ca ²⁺/calmodulin-dependent* protein kinase II α (CaMKIIα) inhibitor with a K_D** of 219 nM for CaMKIIα WT hub. CaMKIIα-IN-1 has good metabolic stability .

HY-P1821A

Myelin basic protein (4-14) TFA 2 Publications Verification MHP4-14 TFA	PKC	Neurological Disease
Myelin Basic Protein (MHP4-14) TFA, a synthetic peptide comprising residues 4-14 of myelin basic protein, is a very selective PKC substrate (K_m=7 μM). Myelin Basic Protein TFA is not phosphorylated by cyclic AMP-dependent protein kinase, casein kinases I and II, Ca ²⁺/calmodulin-dependent protein kinase II, or phosphorylase kinase, and can be routinely used for the assay of protein kinase C with low background in the crude tissue extracts .

HY-120997

E6 Berbamine Berbamine p-nitrobenzoate	Calmodulin Myosin Phosphodiesterase (PDE)	Cardiovascular Disease Cancer
E6 Berbamine (Berbamine p-nitrobenzoate) is a potent calmodulin (CaM) antagonist. E6 Berbamine inhibits the activities of calmodulin-dependent myosin light chain kinase (MLCK) and phosphodiesterase (PDE). E6 Berbamine exhibits anti-leukemic activity. E6 Berbamine can be used in research related to cardiovascular abnormalities and chronic myeloid leukemia .

HY-130368

W-7 5+ Cited Publications	Calmodulin Potassium Channel Phosphodiesterase (PDE) Myosin Apoptosis	Cardiovascular Disease
W-7 is a selective *calmodulin* antagonist. W-7 inhibits the Ca ²⁺-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC₅₀ values of 28 μM and 51 μM, respectively. W-7 induces apoptosis and has antitumor and vascular relaxing activity. W-7 is a blocker of Kv4.3 and can be used for research of arrhythmias .

HY-W170020

PTCA	CaMK	Metabolic Disease
PTCA is a potent *Ca2+/calmodulin-dependent* protein kinase II α (CaMKIIα) ligand with a pK_i** value of 7.2 .

HY-19805A

STO-609 acetate	CaMK AMPK Autophagy	Metabolic Disease
STO-609 acetate is a selective and cell-permeable inhibitor of the Ca ²⁺/calmodulin-dependent protein kinase kinase (CaM-KK), with K_i values of 80 and 15 ng/mL for recombinant CaM-KKα and CaM-KKβ, respectively. STO-609 acetate inhibits AMP-activated protein kinase kinase (AMPKK) activity in HeLa cell lysates with an IC₅₀ ~0.02 g/ml.

HY-19230

DY-9760e	Calmodulin NO Synthase CaMK Calcineurin Proteasome Caspase	Cardiovascular Disease
DY-9760e is a calmodulin (CaM) inhibitor. DY-9760e selectively inhibits the activity of various calmodulin-dependent enzymes by antagonizing the Ca²⁺/CaM complex, exhibiting the strongest inhibitory activity against nNOS, *CaM kinase* II, and calcineurin (K_i: 0.9, 1.4, and 2.0 μM, respectively). DY-9760e inhibits excessive nitric oxide production and protein tyrosine nitration, as well as the activation of calpain and caspase-3**. DY-9760e reduces infarct size, improves cardiac function, and inhibits oxidative stress and cell death. DY-9760e can be used in research on the treatment of myocardial infarction, cerebral ischemia, and other diseases .

HY-P1479

Calmodulin-Dependent Protein Kinase II (290-309)	Autophagy CaMK	Neurological Disease
Calmodulin-Dependent Protein Kinase II (290-309) is a potent CaMK antagonist with an IC₅₀ of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .

HY-137658

Purine riboside triphosphate PTP	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis CaMK	Metabolic Disease
Purine riboside-5'-O-triphosphate, an active metabolite of Nebularine (HY-103694), acts as an inhibitor of DNA primase ATP and GTP polymerization activities, with IC₅₀ values of 35 µM and 28 µM for the human enzyme, respectively. Purine riboside-5'-O-triphosphate also inhibits calmodulin-dependent protein kinase II (CaMKII) with a K_i value of 590 µM .

HY-P5525

AC3-I, myristoylated Autocamtide-3 Derived Inhibitory Peptide	CaMK	Others
AC3-I, myristoylated is a biological active peptide. (This is a myristoylated form of Autocamtide-3-Derived Inhibitory Peptide (AC3-I), a highly specific inhibitor of Calmodulin-Dependent Protein Kinase ll (CaMKII) that is resistant to proteolysis. AC3-I is derived from Autocamtide-3, a substrate for CaMKII, with the Thr-9 phosphorylation site substituted with Ala.)

HY-P1479A

Calmodulin-Dependent Protein Kinase II(290-309) acetate	Autophagy CaMK	Neurological Disease
Calmodulin-Dependent Protein Kinase II (290-309) acetate is a potent CaMK antagonist with an IC₅₀ of 52 nM for inhibition of Ca2+/calmodulin-dependent protein kinase II .

HY-P1874

Calmodulin-Dependent Protein Kinase II (281-309)	Calmodulin	Neurological Disease
Calmodulin-Dependent Protein Kinase II (281-309) is a peptide of calcium/calmodulin-dependent protein kinase II (CaM-kinase II) .

HY-P10316

CaMKI(299-320) Calmodulin-dependent Protein Kinase I (299-320) Binding Domain	CaMK	Others
CaMKI (299-320) refers to a peptide consisting of residues 299-320 of Calcium/calmodulin-dependent protein kinase I (CaMKI). CaMKI (299-320), as a protein kinase, has a high affinity interaction with Ca ²⁺-CAM (K_d≤1 nM≤1 nM), which can phosphorylate specific substrate proteins, thereby regulating their activity. CaMKI (299-320) contains the CAM-binding domain and the self-inhibition domain, and CaMKI (299-320) can be used to study cell physiological processes, including cell proliferation, differentiation, and apoptosis .

HY-P10499

*[Ala286]-Calmodulin-Dependent* Protein Kinase II (281-302)**	CaMK	Others
[Ala286]-Calmodulin-Dependent Protein Kinase II (281-302) is a modified fragment of calcium/calmodulin-dependent protein kinase II that contains the active domain of CaMKII and has an alanine substitution at position 286. [Ala286]-Calmodulin-Dependent Protein Kinase II (281-302) can be used to develop more potent CaMKII inhibitors .

HY-P3811

Autocamtide-3	CaMK	Neurological Disease
Autocamtide-3, a 13-amino-acid peptide containing Thr287, is a selective *CaMKII (Ca ²⁺/calmodulin-dependent* kinase II)** (CaMK) substrate .

HY-P3944

Calmodulin Dependent Protein Kinase Substrate	CaMK	Neurological Disease
Calmodulin Dependent Protein Kinase Substrate is a Ca ²⁺- and **calmodulin (CaM)-dependent protein kinase (CaMK*) substrate peptide. Calmodulin Dependent* Protein Kinase Substrate is a synthetic peptide substrate for protein kinases .

HY-111093

Protein kinase inhibitor 8	CaMK	Neurological Disease
Protein kinase inhibitor 8 (Compound CK59) is a calmodulin-dependent protein kinase II (CaMKII) inhibitor. By inhibiting the activity of CaMKII, Protein kinase inhibitor 8 can attenuate the cytotoxicity induced by perfluorooctane sulfonic acid (PFOS) and alleviate the downregulation of GLT-1 expression caused by PFOS, thereby reducing neuronal damage. Protein kinase inhibitor 8 may be useful in research related to neurodegenerative diseases .

HY-P3943

Calmodulin Dependent Protein Kinase Substrate Analog	CaMK	Neurological Disease
Calmodulin Dependent Protein Kinase Substrate Analog is a Ca ²⁺- and **calmodulin (CaM)-dependent protein kinase (CaMK*) substrate peptide. Calmodulin Dependent* Protein Kinase Substrate Analog is a synthetic peptide substrate for protein kinases .

HY-137658A

Purine riboside-5'-O-triphosphate sodium PTP tetrasodium	Nucleoside Antimetabolite/Analog DNA/RNA Synthesis CaMK	Metabolic Disease
Purine riboside-5'-O-triphosphate sodium, an active metabolite of Nebularine (HY-103694), acts as an inhibitor of DNA primase ATP and GTP polymerization activities, with IC₅₀ values of 35 µM and 28 µM for the human enzyme, respectively. Purine riboside-5'-O-triphosphate sodium inhibits calmodulin-dependent protein kinase II (CaMKII) with a K_i value of 590 µM .

HY-108599R

DCP-LA (Standard) FR236924 (Standard)	Reference Standards PKC CaMK Phosphatase Apoptosis	Neurological Disease
DCP-LA (Standard) is the analytical standard of DCP-LA. This product is intended for research and analytical applications. DCP-LA (FR236924), a linoleic acid derivative, selectively and directly activates PKCε. DCP-LA activates Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) and inhibits protein phosphatase-1 (PP-1) to stimulate AMPA receptor exocytosis. DCP-LA inhibits activation of caspase-3/-9 and protects neurons at least in part from oxidative stress-induced apoptosis[1][2][3].

HY-156104

CaMKIIα-PHOTAC	PROTACs CaMK	Neurological Disease
CaMKIIα-PHOTAC is a photochemically targeted chimera (PHOTAC) targeting Ca2+/calmodulin-dependent protein kinase II α (CaMKIIα). Molecules such as PHOTAC can catalyze the ubiquitination and degradation of target proteins through the endogenous proteasome under specific wavelengths of light. CaMKIIα-PHOTAC reduces synaptic function under light conditions, and it attenuates the intensity of evoked field excitatory postsynaptic potentials in the mouse hippocampus in response to physiological stimuli. CaMKIIα-PHOTAC plays a critical role in maintaining long-term potentiation and memory capacity in subcellular dendritic domains .

HY-P1716

Neuropeptide DF2	PKC	Neurological Disease
Neuropeptide DF2 is a DRNFLRFamide neuropeptide orignally isolated from crayfish. which enhances transmitter release and stimulates the amplitude of excitatory post-synaptic potentials (EPSP) through the calcium/calmodulin-dependent protein kinase .

HY-P10367

Ziptide	MAPKAPK2 (MK2) Checkpoint Kinase (Chk) AMPK	Others
Ziptide is a substrate for MAPK activated protein kinase 2 (MAPKAPK2, K_m = 5 μM), MAPKAPK3 (K_m = 30 μM), PARK (K_m = 40 μM), checkpoint kinase 1 (Chk1, K_m = 5 μM), AMP-activated protein kinase (AMPK, K_m = 75 μM), and calcium/calmodulin-dependent protein kinase II (CamKII, K_m = 300 μM) .

HY-E70950

Calmodulin-dependent Protein Kinase II, Rat	Ser/Thr Kinase	Neurological Disease
Calmodulin-dependent protein kinase II, Rat, is a serine-threonine protein kinase involved in neurotransmitter release, stimulation-induced gene expression control, and microtubule-associated protein phosphorylation.

HY-114554

KS 619-1	Phosphodiesterase (PDE) PKC Bacterial	Infection
KS 619-1 is a Ca ²⁺/calmodulin-dependent cyclic nucleotide phosphodiesterase inhibitor. KS 619-1 exhibits strong inhibitory activity against this enzyme derived from bovine brain and heart, but shows weak inhibitory effects on calmodulin-independent phosphodiesterase and *protein kinase* C*. KS 619-1 displays weak antibacterial activity against Staphylococcus aureus* .

HY-100912R

W-7 hydrochloride (Standard)	Reference Standards Phosphodiesterase (PDE) Myosin Apoptosis Calmodulin Potassium Channel	Cancer
W-7 (hydrochloride) (Standard) is the analytical standard of W-7 (hydrochloride) (HY-100912). This product is intended for research and analytical applications. W-7 hydrochloride is a selective calmodulin antagonist. W-7 hydrochloride inhibits the Ca2+-calmodulin-dependent phosphodiesterase and myosin light chain kinase with IC50 values of 28 μM and 51 μM, respectively. W-7 hydrochloride induces apoptosis and has antitumor and vascular relaxing activity. W-7 hydrochloride is a blocker of Kv4.3 and can be used for research of arrhythmias .

HY-116153

HUHS2002	Cholinesterase (ChE)	Neurological Disease
HUHS2002 is a free fatty acid derivative with the ability to enhance α7 cholinergic receptor activity. HUHS2002 enhances whole-cell membrane currents of α7 ACh receptors expressed in Xenopus oocytes in a concentration-dependent manner. The effects of HUHS2002 were blocked in the presence of the Ca2 /calmodulin-dependent protein kinase II (CaMKII) inhibitor KN-93. HUHS2002 activated CaMKII in cultured rodent hippocampal neurons, and this activation was abolished by KN-93. HUHS2002 also partially inhibited the activity of protein phosphatase 1 (PP1) in a cell-free PP1 activity assay .

HY-W720917

Junicedric acid	CaMK PKC Amyloid-β Apoptosis	Neurological Disease
Junicedric acid is a diterpenoid compound that can be isolated from the resin of the Araucaria araucana tree. Junicedric acid exerts neuroprotective activity by increasing intracellular calcium levels in hippocampal neurons, activating PKC and calcium/calmodulin-dependent protein kinase (CaMKII), and preventing Amyloid-β oligomer-induced synaptic protein loss, apoptosis, and long-term potentiation (LTP) inhibition. Junicedric acid can be used in the study of the pathological mechanisms of neurodegenerative diseases such as Alzheimer's disease .

HY-129980A

NPC-15437		Neurological Disease Cancer
NPC-15437 is a selective PKC inhibitor with an IC₅₀ of 19 µM. NPC-15437 competitively inhibits phorbol ester- (K_i of 5 µM) and phosphatidylserine-induced (K_i of 12 µM) PKC activity. NPC-15437 does not inhibits cAMP-dependent or calcium/calmodulin-dependent protein kinases. NPC-15437 augments TRAIL-induced cell death in non-small cell lung cancer and medulloblastoma cells. NPC-15437 can be used for the research of non-small cell lung cancer, medulloblastoma, and neurological disease .

Cat. No.	Product Name	Target	Research Area